Clinical Trials
70 trialsTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
National Cancer Institute "Cancer Moonshot Biobank"
National Cancer Institute (NCI)
Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
National Cancer Institute (NCI)
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Compugen Ltd
LONGEVITI
University of Alberta
iCaRe2
University of Nebraska
Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer
M.D. Anderson Cancer Center
CER
Cancer Support Community, Research and Training Institute, Philadelphia
SURGE
Colorado State University
EHCancer
Zagazig University
DETERMINE
Cancer Research UK
Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring
Carevive Systems, Inc.
SELECT-CAR-NK
Essen Biotech
IT-TCP POS
Azienda Ospedaliero-Universitaria di Parma
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
Memorial Sloan Kettering Cancer Center
CAMPERR
Adela, Inc
POSBIO-CRC
AC Camargo Cancer Center
DETERMINE
Cancer Research UK
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Case Comprehensive Cancer Center
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
MITOX
IRCCS San Raffaele
AVR-CHEMO
Arab American University (Palestine)
ARC-12
Arcus Biosciences, Inc.
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
Barbara Ann Karmanos Cancer Institute
Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid
Washington University School of Medicine
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
Washington University School of Medicine
GustaborPilot
Wuerzburg University Hospital
AMPLIFY
University of Alabama at Birmingham
CARTIER
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
Karyopharm Therapeutics Inc
The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
Cedars-Sinai Medical Center
Proteomic Analysis of Patients Undergoing Bariatric Surgery
Universidade Federal de Pernambuco
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
ROOT
Taproot Health
Survivorship
University of Modena and Reggio Emilia
Evaluating the Effect of a Mobile Audio Companion (Elly) to Reduce Anxiety in Cancer Patients
Cedars-Sinai Medical Center
Heart Rate Variability, Vagus Nerve and Cancer
Centre Hospitalier Henri Duffaut - Avignon
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Celgene
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Case Comprehensive Cancer Center
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Celgene
LNA-i-miR221
Azienda Ospedaliera Universitaria Mater Domini, Catanzaro
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
University of Wisconsin, Madison
PREDICARE
LEO Pharma
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Incyte Corporation